Spots Global Cancer Trial Database for Cabazitaxel in Platinum Refractory Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Cabazitaxel in Platinum Refractory Ovarian Cancer
Official Title: Cabazitaxel in Platinum Refractory Ovarian Cancer. A Phase II Trial
Study ID: NCT01747239
Conditions
Interventions
Study Description
Brief Summary: Ovarian cancer patients are considered platinum refractory if their disease worsens during primary platinum treatment or if they have no effect of the treatment. This constitutes a major therapeutic problem and new treatment approaches are highly needed. Cabazitaxel (Jevtana®) is a new taxane with effect in breast and prostatic cancer. In both tumors it has effect in patients refractory to taxotere. Consequently, it could be anticipated that cabazitaxel may have an effect in platinum refractory ovarian cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Department of Oncology, Aalborg Hospital, Aalborg, , Denmark
Herlev Hospital, Herlev, , Denmark
Department of Oncology, Odense University Hospital, Odense, , Denmark
Department of Oncology, Vejle Hospital, Vejle, , Denmark
Contact Details
Name: Anders Jakobsen, DMSc
Affiliation: Vejle Hospital
Role: STUDY_CHAIR
Name: Christine V Madsen, MD
Affiliation: Vejle Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
